Astria Therapeutics Inc

詳細情報 Astria Therapeutics Inc 企業名

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

企業情報

企業コードATXS

会社名Astria Therapeutics Inc

上場日Jun 25, 2015

最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.

従業員数78

証券種類Ordinary Share

決算期末Jun 25

本社所在地22 Boston Wharf Road

都市BOSTON

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号02210

電話番号16173491971

ウェブサイトhttps://astriatx.com/

企業コードATXS

上場日Jun 25, 2015

最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jonathan Violin, Ph.D.

Independent Director

263.32K

--

Mr. Noah Clauser

Chief Financial Officer

--

Ms. Elizabeth Higgins

Investor Relations

--

Dr. Joanne T. Beck, Ph.D.

Independent Director

--

Dr. Jill C. Milne, Ph.D.

President, Chief Executive Officer, Co-Founder, Director

--

Mr. Gregg A. Lapointe, CPA

Independent Director

--

Mr. Andrew Komjathy

Chief Commercial Officer

--

Dr. Sunil Agarwal, M.D.

Independent Director

--

Mr. Benjamin Scott Harshbarger

Chief Legal Officer

--

Ms. Andrea Matthews

Chief Business Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jonathan Violin, Ph.D.

Independent Director

263.32K

--

Mr. Noah Clauser

Chief Financial Officer

--

Ms. Elizabeth Higgins

Investor Relations

--

Dr. Joanne T. Beck, Ph.D.

Independent Director

--

Dr. Jill C. Milne, Ph.D.

President, Chief Executive Officer, Co-Founder, Director

--

Mr. Gregg A. Lapointe, CPA

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Fri, May 16

株主統計

種類

株主統計

比率

Perceptive Advisors LLC

11.49%

RA Capital Management, LP

9.05%

Fidelity Management & Research Company LLC

8.52%

Vestal Point Capital, LP

7.41%

Forbion Capital Partners

6.77%

Other

56.77%

株主統計

比率

Perceptive Advisors LLC

11.49%

RA Capital Management, LP

9.05%

Fidelity Management & Research Company LLC

8.52%

Vestal Point Capital, LP

7.41%

Forbion Capital Partners

6.77%

Other

56.77%

種類

株主統計

比率

Investment Advisor

32.69%

Venture Capital

23.81%

Hedge Fund

19.93%

Investment Advisor/Hedge Fund

16.86%

Private Equity

11.49%

Research Firm

1.00%

Individual Investor

0.49%

Pension Fund

0.21%

Bank and Trust

0.19%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

263

60.20M

106.68%

-10.73M

2025Q1

281

59.08M

104.77%

-12.46M

2024Q4

268

59.35M

105.17%

-9.44M

2024Q3

247

57.14M

101.27%

-10.09M

2024Q2

228

56.25M

102.41%

-8.30M

2024Q1

210

58.30M

106.65%

+7.30M

2023Q4

179

37.20M

102.69%

+9.26M

2023Q3

171

23.97M

88.11%

-4.33M

2023Q2

175

25.83M

94.82%

-888.95K

2023Q1

166

24.59M

91.65%

-670.60K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Perceptive Advisors LLC

6.49M

11.49%

--

Mar 31, 2025

RA Capital Management, LP

5.11M

9.05%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

4.81M

8.52%

-846.00K

-14.97%

Mar 31, 2025

Vestal Point Capital, LP

4.18M

7.41%

--

Mar 31, 2025

Forbion Capital Partners

3.82M

6.77%

+950.00K

+33.07%

Mar 31, 2025

Fairmount Funds Management LLC

3.55M

6.3%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.40M

6.03%

-66.23K

-1.91%

Mar 31, 2025

Millennium Management LLC

2.94M

5.21%

+1.30M

+79.78%

Jun 13, 2025

TCG Crossover Management, LLC

2.76M

4.89%

--

Mar 31, 2025

The Vanguard Group, Inc.

2.64M

4.68%

-29.10K

-1.09%

Mar 31, 2025

詳細を見る

6.890USD

Astria Therapeutics Inc

6.890

概要

企業名

金融